Rationale and design of the CAPAMIS study: Effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke

Background The 23-valent polysaccharide pneumococcal vaccine (PPV-23) is recommended for elderly and high-risk people, although its effectiveness is controversial. Some studies have reported an increasing risk of acute vascular events among patients with pneumonia, and a recent case-control study ha...

Full description

Saved in:
Bibliographic Details
Published inBMC public health Vol. 10; no. 1; p. 25
Main Authors Vila-Corcoles, Angel, Hospital-Guardiola, Inmaculada, Ochoa-Gondar, Olga, de Diego, Cinta, Salsench, Elisabet, Raga, Xavier, Fuentes-Bellido, Cruz M
Format Journal Article
LanguageEnglish
Published London BioMed Central 19.01.2010
BioMed Central Ltd
BMC
Subjects
Online AccessGet full text
ISSN1471-2458
1471-2458
DOI10.1186/1471-2458-10-25

Cover

Abstract Background The 23-valent polysaccharide pneumococcal vaccine (PPV-23) is recommended for elderly and high-risk people, although its effectiveness is controversial. Some studies have reported an increasing risk of acute vascular events among patients with pneumonia, and a recent case-control study has reported a reduction in the risk of myocardial infarction among patients vaccinated with PPV-23. Given that animal experiments have shown that pneumococcal vaccination reduces the extent of atherosclerotic lesions, it has been hypothesized that PPV-23 could protect against acute vascular events by an indirect effect preventing pneumonia or by a direct effect on oxidized low-density lipoproteins. The main objective of this study is to evaluate the clinical effectiveness of PPV-23 in reducing the risk of pneumonia and acute vascular events (related or nonrelated with prior pneumonia) in the general population over 60 years. Methods/Design Cohort study including 27,000 individuals 60 years or older assigned to nine Primary Care Centers in the region of Tarragona, Spain. According to the reception of PPV-23 before the start of the study, the study population will be divided into vaccinated and nonvaccinated groups, which will be followed during a consecutive 30-month period. Primary Care and Hospitals discharge databases will initially be used to identify study events (community-acquired pneumonia, hospitalisation for acute myocardial infarction and stroke), but all cases will be further validated by checking clinical records. Multivariable Cox regression analyses estimating hazard ratios (adjusted for age, sex and comorbidities) will be used to estimate vaccine effectiveness. Discussion The results of the study will contribute to clarify the controversial effect of the PPV-23 in preventing community-acquired pneumonia and they will be critical in determining the posible role of pneumococcal vaccination in cardiovascular prevention.
AbstractList Background The 23-valent polysaccharide pneumococcal vaccine (PPV-23) is recommended for elderly and high-risk people, although its effectiveness is controversial. Some studies have reported an increasing risk of acute vascular events among patients with pneumonia, and a recent case-control study has reported a reduction in the risk of myocardial infarction among patients vaccinated with PPV-23. Given that animal experiments have shown that pneumococcal vaccination reduces the extent of atherosclerotic lesions, it has been hypothesized that PPV-23 could protect against acute vascular events by an indirect effect preventing pneumonia or by a direct effect on oxidized low-density lipoproteins. The main objective of this study is to evaluate the clinical effectiveness of PPV-23 in reducing the risk of pneumonia and acute vascular events (related or nonrelated with prior pneumonia) in the general population over 60 years. Methods/Design Cohort study including 27,000 individuals 60 years or older assigned to nine Primary Care Centers in the region of Tarragona, Spain. According to the reception of PPV-23 before the start of the study, the study population will be divided into vaccinated and nonvaccinated groups, which will be followed during a consecutive 30-month period. Primary Care and Hospitals discharge databases will initially be used to identify study events (community-acquired pneumonia, hospitalisation for acute myocardial infarction and stroke), but all cases will be further validated by checking clinical records. Multivariable Cox regression analyses estimating hazard ratios (adjusted for age, sex and comorbidities) will be used to estimate vaccine effectiveness. Discussion The results of the study will contribute to clarify the controversial effect of the PPV-23 in preventing community-acquired pneumonia and they will be critical in determining the posible role of pneumococcal vaccination in cardiovascular prevention.
The 23-valent polysaccharide pneumococcal vaccine (PPV-23) is recommended for elderly and high-risk people, although its effectiveness is controversial. Some studies have reported an increasing risk of acute vascular events among patients with pneumonia, and a recent case-control study has reported a reduction in the risk of myocardial infarction among patients vaccinated with PPV-23. Given that animal experiments have shown that pneumococcal vaccination reduces the extent of atherosclerotic lesions, it has been hypothesized that PPV-23 could protect against acute vascular events by an indirect effect preventing pneumonia or by a direct effect on oxidized low-density lipoproteins. The main objective of this study is to evaluate the clinical effectiveness of PPV-23 in reducing the risk of pneumonia and acute vascular events (related or nonrelated with prior pneumonia) in the general population over 60 years. Cohort study including 27,000 individuals 60 years or older assigned to nine Primary Care Centers in the region of Tarragona, Spain. According to the reception of PPV-23 before the start of the study, the study population will be divided into vaccinated and nonvaccinated groups, which will be followed during a consecutive 30-month period. Primary Care and Hospitals discharge databases will initially be used to identify study events (community-acquired pneumonia, hospitalisation for acute myocardial infarction and stroke), but all cases will be further validated by checking clinical records. Multivariable Cox regression analyses estimating hazard ratios (adjusted for age, sex and comorbidities) will be used to estimate vaccine effectiveness. The results of the study will contribute to clarify the controversial effect of the PPV-23 in preventing community-acquired pneumonia and they will be critical in determining the possible role of pneumococcal vaccination in cardiovascular prevention.
The 23-valent polysaccharide pneumococcal vaccine (PPV-23) is recommended for elderly and high-risk people, although its effectiveness is controversial. Some studies have reported an increasing risk of acute vascular events among patients with pneumonia, and a recent case-control study has reported a reduction in the risk of myocardial infarction among patients vaccinated with PPV-23. Given that animal experiments have shown that pneumococcal vaccination reduces the extent of atherosclerotic lesions, it has been hypothesized that PPV-23 could protect against acute vascular events by an indirect effect preventing pneumonia or by a direct effect on oxidized low-density lipoproteins. The main objective of this study is to evaluate the clinical effectiveness of PPV-23 in reducing the risk of pneumonia and acute vascular events (related or nonrelated with prior pneumonia) in the general population over 60 years. Cohort study including 27,000 individuals 60 years or older assigned to nine Primary Care Centers in the region of Tarragona, Spain. According to the reception of PPV-23 before the start of the study, the study population will be divided into vaccinated and nonvaccinated groups, which will be followed during a consecutive 30-month period. Primary Care and Hospitals discharge databases will initially be used to identify study events (community-acquired pneumonia, hospitalisation for acute myocardial infarction and stroke), but all cases will be further validated by checking clinical records. Multivariable Cox regression analyses estimating hazard ratios (adjusted for age, sex and comorbidities) will be used to estimate vaccine effectiveness. The results of the study will contribute to clarify the controversial effect of the PPV-23 in preventing community-acquired pneumonia and they will be critical in determining the posible role of pneumococcal vaccination in cardiovascular prevention.
The 23-valent polysaccharide pneumococcal vaccine (PPV-23) is recommended for elderly and high-risk people, although its effectiveness is controversial. Some studies have reported an increasing risk of acute vascular events among patients with pneumonia, and a recent case-control study has reported a reduction in the risk of myocardial infarction among patients vaccinated with PPV-23. Given that animal experiments have shown that pneumococcal vaccination reduces the extent of atherosclerotic lesions, it has been hypothesized that PPV-23 could protect against acute vascular events by an indirect effect preventing pneumonia or by a direct effect on oxidized low-density lipoproteins. The main objective of this study is to evaluate the clinical effectiveness of PPV-23 in reducing the risk of pneumonia and acute vascular events (related or nonrelated with prior pneumonia) in the general population over 60 years.BACKGROUNDThe 23-valent polysaccharide pneumococcal vaccine (PPV-23) is recommended for elderly and high-risk people, although its effectiveness is controversial. Some studies have reported an increasing risk of acute vascular events among patients with pneumonia, and a recent case-control study has reported a reduction in the risk of myocardial infarction among patients vaccinated with PPV-23. Given that animal experiments have shown that pneumococcal vaccination reduces the extent of atherosclerotic lesions, it has been hypothesized that PPV-23 could protect against acute vascular events by an indirect effect preventing pneumonia or by a direct effect on oxidized low-density lipoproteins. The main objective of this study is to evaluate the clinical effectiveness of PPV-23 in reducing the risk of pneumonia and acute vascular events (related or nonrelated with prior pneumonia) in the general population over 60 years.Cohort study including 27,000 individuals 60 years or older assigned to nine Primary Care Centers in the region of Tarragona, Spain. According to the reception of PPV-23 before the start of the study, the study population will be divided into vaccinated and nonvaccinated groups, which will be followed during a consecutive 30-month period. Primary Care and Hospitals discharge databases will initially be used to identify study events (community-acquired pneumonia, hospitalisation for acute myocardial infarction and stroke), but all cases will be further validated by checking clinical records. Multivariable Cox regression analyses estimating hazard ratios (adjusted for age, sex and comorbidities) will be used to estimate vaccine effectiveness.METHODS/DESIGNCohort study including 27,000 individuals 60 years or older assigned to nine Primary Care Centers in the region of Tarragona, Spain. According to the reception of PPV-23 before the start of the study, the study population will be divided into vaccinated and nonvaccinated groups, which will be followed during a consecutive 30-month period. Primary Care and Hospitals discharge databases will initially be used to identify study events (community-acquired pneumonia, hospitalisation for acute myocardial infarction and stroke), but all cases will be further validated by checking clinical records. Multivariable Cox regression analyses estimating hazard ratios (adjusted for age, sex and comorbidities) will be used to estimate vaccine effectiveness.The results of the study will contribute to clarify the controversial effect of the PPV-23 in preventing community-acquired pneumonia and they will be critical in determining the possible role of pneumococcal vaccination in cardiovascular prevention.DISCUSSIONThe results of the study will contribute to clarify the controversial effect of the PPV-23 in preventing community-acquired pneumonia and they will be critical in determining the possible role of pneumococcal vaccination in cardiovascular prevention.
Background The 23-valent polysaccharide pneumococcal vaccine (PPV-23) is recommended for elderly and high-risk people, although its effectiveness is controversial. Some studies have reported an increasing risk of acute vascular events among patients with pneumonia, and a recent case-control study has reported a reduction in the risk of myocardial infarction among patients vaccinated with PPV-23. Given that animal experiments have shown that pneumococcal vaccination reduces the extent of atherosclerotic lesions, it has been hypothesized that PPV-23 could protect against acute vascular events by an indirect effect preventing pneumonia or by a direct effect on oxidized low-density lipoproteins. The main objective of this study is to evaluate the clinical effectiveness of PPV-23 in reducing the risk of pneumonia and acute vascular events (related or nonrelated with prior pneumonia) in the general population over 60 years. Methods/Design Cohort study including 27,000 individuals 60 years or older assigned to nine Primary Care Centers in the region of Tarragona, Spain. According to the reception of PPV-23 before the start of the study, the study population will be divided into vaccinated and nonvaccinated groups, which will be followed during a consecutive 30-month period. Primary Care and Hospitals discharge databases will initially be used to identify study events (community-acquired pneumonia, hospitalisation for acute myocardial infarction and stroke), but all cases will be further validated by checking clinical records. Multivariable Cox regression analyses estimating hazard ratios (adjusted for age, sex and comorbidities) will be used to estimate vaccine effectiveness. Discussion The results of the study will contribute to clarify the controversial effect of the PPV-23 in preventing community-acquired pneumonia and they will be critical in determining the posible role of pneumococcal vaccination in cardiovascular prevention.
Abstract Background The 23-valent polysaccharide pneumococcal vaccine (PPV-23) is recommended for elderly and high-risk people, although its effectiveness is controversial. Some studies have reported an increasing risk of acute vascular events among patients with pneumonia, and a recent case-control study has reported a reduction in the risk of myocardial infarction among patients vaccinated with PPV-23. Given that animal experiments have shown that pneumococcal vaccination reduces the extent of atherosclerotic lesions, it has been hypothesized that PPV-23 could protect against acute vascular events by an indirect effect preventing pneumonia or by a direct effect on oxidized low-density lipoproteins. The main objective of this study is to evaluate the clinical effectiveness of PPV-23 in reducing the risk of pneumonia and acute vascular events (related or nonrelated with prior pneumonia) in the general population over 60 years. Methods/Design Cohort study including 27,000 individuals 60 years or older assigned to nine Primary Care Centers in the region of Tarragona, Spain. According to the reception of PPV-23 before the start of the study, the study population will be divided into vaccinated and nonvaccinated groups, which will be followed during a consecutive 30-month period. Primary Care and Hospitals discharge databases will initially be used to identify study events (community-acquired pneumonia, hospitalisation for acute myocardial infarction and stroke), but all cases will be further validated by checking clinical records. Multivariable Cox regression analyses estimating hazard ratios (adjusted for age, sex and comorbidities) will be used to estimate vaccine effectiveness. Discussion The results of the study will contribute to clarify the controversial effect of the PPV-23 in preventing community-acquired pneumonia and they will be critical in determining the posible role of pneumococcal vaccination in cardiovascular prevention.
Doc number: 25 Abstract Background: The 23-valent polysaccharide pneumococcal vaccine (PPV-23) is recommended for elderly and high-risk people, although its effectiveness is controversial. Some studies have reported an increasing risk of acute vascular events among patients with pneumonia, and a recent case-control study has reported a reduction in the risk of myocardial infarction among patients vaccinated with PPV-23. Given that animal experiments have shown that pneumococcal vaccination reduces the extent of atherosclerotic lesions, it has been hypothesized that PPV-23 could protect against acute vascular events by an indirect effect preventing pneumonia or by a direct effect on oxidized low-density lipoproteins. The main objective of this study is to evaluate the clinical effectiveness of PPV-23 in reducing the risk of pneumonia and acute vascular events (related or nonrelated with prior pneumonia) in the general population over 60 years. Methods/Design: Cohort study including 27,000 individuals 60 years or older assigned to nine Primary Care Centers in the region of Tarragona, Spain. According to the reception of PPV-23 before the start of the study, the study population will be divided into vaccinated and nonvaccinated groups, which will be followed during a consecutive 30-month period. Primary Care and Hospitals discharge databases will initially be used to identify study events (community-acquired pneumonia, hospitalisation for acute myocardial infarction and stroke), but all cases will be further validated by checking clinical records. Multivariable Cox regression analyses estimating hazard ratios (adjusted for age, sex and comorbidities) will be used to estimate vaccine effectiveness. Discussion: The results of the study will contribute to clarify the controversial effect of the PPV-23 in preventing community-acquired pneumonia and they will be critical in determining the posible role of pneumococcal vaccination in cardiovascular prevention.
ArticleNumber 25
Audience Academic
Author Vila-Corcoles, Angel
Salsench, Elisabet
Fuentes-Bellido, Cruz M
Hospital-Guardiola, Inmaculada
Raga, Xavier
Ochoa-Gondar, Olga
de Diego, Cinta
AuthorAffiliation 3 Department of Medicine and Surgery, Faculty of Medicine and Health Sciences, Rovira i Virgili University, Tarragona, Spain
1 Primary Care Service of Tarragona-Valls, Institut Catalá de la Salut, Tarragona, Spain
2 Department of Microbiology and Laboratory, Hospital Santa Tecla, Tarragona, Spain
AuthorAffiliation_xml – name: 2 Department of Microbiology and Laboratory, Hospital Santa Tecla, Tarragona, Spain
– name: 1 Primary Care Service of Tarragona-Valls, Institut Catalá de la Salut, Tarragona, Spain
– name: 3 Department of Medicine and Surgery, Faculty of Medicine and Health Sciences, Rovira i Virgili University, Tarragona, Spain
Author_xml – sequence: 1
  givenname: Angel
  surname: Vila-Corcoles
  fullname: Vila-Corcoles, Angel
  organization: Primary Care Service of Tarragona-Valls, Institut Catalá de la Salut
– sequence: 2
  givenname: Inmaculada
  surname: Hospital-Guardiola
  fullname: Hospital-Guardiola, Inmaculada
  organization: Primary Care Service of Tarragona-Valls, Institut Catalá de la Salut
– sequence: 3
  givenname: Olga
  surname: Ochoa-Gondar
  fullname: Ochoa-Gondar, Olga
  email: oochoa.tarte.ics@gencat.cat
  organization: Primary Care Service of Tarragona-Valls, Institut Catalá de la Salut
– sequence: 4
  givenname: Cinta
  surname: de Diego
  fullname: de Diego, Cinta
  organization: Primary Care Service of Tarragona-Valls, Institut Catalá de la Salut
– sequence: 5
  givenname: Elisabet
  surname: Salsench
  fullname: Salsench, Elisabet
  organization: Primary Care Service of Tarragona-Valls, Institut Catalá de la Salut
– sequence: 6
  givenname: Xavier
  surname: Raga
  fullname: Raga, Xavier
  organization: Department of Microbiology and Laboratory, Hospital Santa Tecla
– sequence: 7
  givenname: Cruz M
  surname: Fuentes-Bellido
  fullname: Fuentes-Bellido, Cruz M
  organization: Primary Care Service of Tarragona-Valls, Institut Catalá de la Salut, Department of Medicine and Surgery, Faculty of Medicine and Health Sciences, Rovira i Virgili University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20085658$$D View this record in MEDLINE/PubMed
BookMark eNp9kktv1TAQRiNURB-wZocisYAFaf2InaQLpKuqQKUiEI-1NXEmty6J3dpOpftz-Kc497alrShKpFiTM0ej8bebbVlnMcteUrJPaS0PaFnRgpWiLigpmHiS7dxWtu6ct7PdEM4JoVUt2LNsmxFSCynqnez3N4jGWRgwB9vlHQaztLnr83iG-dHi6-Lzyfc8xKlbHebHfY86miu0GMLMXFicRqed1jDkV6C1sWtbDkswNsRcu3GcrImrAvTlZDx21z3WwLsc9BQxH1dOg-9MUhjbg9cbQxomRO9-4fPsaQ9DwBfX373s54fjH0efitMvH0-OFqeFlqyKBZdQtS3RAGlK0vZVw9q25VJ2tWhKUbZNT2rsCal6CbQSWnYMgYCssELeA9_LTjbezsG5uvBmBL9SDoxaF5xfKvDR6AFV17RYt0BFWmNZclETKdMUDXakJ7ziyfV-47qY2hE7jTZ6GO5J7_-x5kwt3ZViNUuvSII31wLvLicMUY0maBwGsOimoCpesppyXiby7X9JKiUpWcOYTOjrB-i5m3y6-5kSlJW84fVfaplCodKVuDShnqVqwWhDuCg5SdT-P6j0dDganULam1S_1_Dq7kpud3ETxQSIDaC9C8Fjr7SJ6zglsxkUJWqOvJpDreZQz5X1qg4e9N2oH-8gm46QSLtEf2cPj7T8AUYiEls
CitedBy_id crossref_primary_10_1016_j_jstrokecerebrovasdis_2013_12_047
crossref_primary_10_1016_j_medcle_2021_03_034
crossref_primary_10_4161_hv_28444
crossref_primary_10_1016_j_medcli_2021_03_027
crossref_primary_10_1111_jch_13948
crossref_primary_10_1016_j_vaccine_2013_11_017
crossref_primary_10_1186_1471_2458_12_222
crossref_primary_10_1016_j_medcli_2015_09_015
crossref_primary_10_1093_cid_ciu002
crossref_primary_10_1186_s12889_021_11879_2
crossref_primary_10_1016_j_aprim_2021_102118
crossref_primary_10_1093_ehjqcco_qcaa030
crossref_primary_10_1177_2047487314549512
crossref_primary_10_1016_j_medcle_2015_09_001
crossref_primary_10_1016_j_vaccine_2015_07_062
crossref_primary_10_1136_bmjopen_2020_041577
crossref_primary_10_1016_j_ijid_2020_01_034
crossref_primary_10_1177_2047487318788396
crossref_primary_10_1007_s15010_015_0801_y
crossref_primary_10_1111_ane_12535
Cites_doi 10.1503/cmaj.080734
10.1503/cmaj.081302
10.1016/j.rmed.2008.08.006
10.1016/S0002-9440(10)65677-5
10.1056/NEJMra043430
10.1186/1471-2458-8-222
10.1056/NEJM199701233360402
10.1056/NEJMoa041747
10.1157/13127845
10.1016/S0212-6567(02)79027-6
10.1183/09031936.03.00064102
10.1056/NEJM199512143332408
10.1016/S0264-410X(01)00217-1
10.1016/j.vaccine.2003.09.027
10.1016/j.vaccine.2009.01.013
10.1023/B:EJEP.0000024701.94769.98
10.1016/S1473-3099(08)70134-8
10.1186/1471-2296-1-1
10.1016/S1473-3099(03)00514-0
10.1038/nm876
10.1086/507340
10.1093/eurheartj/ehm035
10.1503/cmaj.070221
10.1086/589246
10.1086/518849
10.1016/S1473-3099(05)70083-9
10.1111/j.1365-2796.2009.02149.x
10.1086/318124
10.1001/archinte.1994.00420230051007
10.1136/thorax.58.5.377
10.1186/1471-2458-6-231
10.1016/S0264-410X(02)00112-3
10.1055/s-2005-925523
10.2165/00002512-199915001-00003
10.2165/00002512-200724100-00001
10.1002/14651858.CD000422.pub2
ContentType Journal Article
Copyright Vila-Corcoles et al; licensee BioMed Central Ltd. 2010 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
COPYRIGHT 2010 BioMed Central Ltd.
2010 Vila-Corcoles et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright ©2010 Vila-Corcoles et al; licensee BioMed Central Ltd. 2010 Vila-Corcoles et al; licensee BioMed Central Ltd.
Copyright_xml – notice: Vila-Corcoles et al; licensee BioMed Central Ltd. 2010 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
– notice: COPYRIGHT 2010 BioMed Central Ltd.
– notice: 2010 Vila-Corcoles et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
– notice: Copyright ©2010 Vila-Corcoles et al; licensee BioMed Central Ltd. 2010 Vila-Corcoles et al; licensee BioMed Central Ltd.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T2
7X7
7XB
88E
8C1
8FE
8FG
8FI
8FJ
8FK
ABJCF
ABUWG
AEUYN
AFKRA
AN0
ATCPS
AZQEC
BENPR
BGLVJ
BHPHI
C1K
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
L6V
M0S
M1P
M7S
PATMY
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
PTHSS
PYCSY
7QL
7U1
7X8
5PM
DOA
DOI 10.1186/1471-2458-10-25
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health and Safety Science Abstracts (Full archive)
Health & Medical Collection (ProQuest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Public Health Database (ProQuest)
ProQuest SciTech Collection
ProQuest Technology Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Materials Science & Engineering Collection
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
British Nursing Database
Agricultural & Environmental Science Collection
ProQuest Central Essentials
ProQuest Central
Technology Collection
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Engineering Collection
ProQuest Health & Medical Collection
Medical Database
Engineering Database
Environmental Science Database
Proquest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Engineering Collection
Environmental Science Collection
Bacteriology Abstracts (Microbiology B)
Risk Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ: Directory of Open Access Journal (DOAJ)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
Technology Collection
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
ProQuest Engineering Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Agricultural & Environmental Science Collection
Health & Safety Science Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Engineering Collection
Engineering Database
ProQuest Public Health
ProQuest One Academic Eastern Edition
British Nursing Index with Full Text
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Environmental Science Collection
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Materials Science & Engineering Collection
Environmental Science Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
Risk Abstracts
Bacteriology Abstracts (Microbiology B)
MEDLINE - Academic
DatabaseTitleList
MEDLINE

MEDLINE - Academic


Publicly Available Content Database
Risk Abstracts
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
EISSN 1471-2458
EndPage 25
ExternalDocumentID oai_doaj_org_article_d9be8ba1500844358066c629ed0f0373
PMC2822825
3579370721
A219035430
20085658
10_1186_1471_2458_10_25
Genre Evaluation Studies
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Spain
Spain, Cataluna, Tarragona
GeographicLocations_xml – name: Spain
– name: Spain, Cataluna, Tarragona
GroupedDBID ---
0R~
23N
2VQ
2WC
2XV
4.4
44B
53G
5VS
6J9
6PF
7X7
7XC
88E
8C1
8FE
8FG
8FH
8FI
8FJ
A8Z
AAFWJ
AAJSJ
AASML
AAWTL
ABDBF
ABJCF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AEUYN
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHSBF
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AN0
AOIJS
ATCPS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BGLVJ
BHPHI
BMC
BNQBC
BPHCQ
BVXVI
C1A
C6C
CCPQU
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EJD
EMB
EMK
EMOBN
ESTFP
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
H13
HCIFZ
HMCUK
HYE
IAO
IHR
INH
INR
IPNFZ
ITC
KQ8
L6V
M1P
M48
M7S
M~E
O5R
O5S
OK1
OVT
P2P
PATMY
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
PTHSS
PUEGO
PYCSY
RBZ
RIG
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
U2A
UKHRP
W2D
WOQ
WOW
XSB
AAYXX
ALIPV
CITATION
-A0
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7T2
7XB
8FK
AZQEC
C1K
DWQXO
GNUQQ
K9.
PKEHL
PQEST
PQUKI
PRINS
7QL
7U1
7X8
5PM
ID FETCH-LOGICAL-c627t-36a7bb0caaffe0bf792bbb366d859454b9f08ef007f6a175c6d2ea0a67e7e3fa3
IEDL.DBID M48
ISSN 1471-2458
IngestDate Wed Aug 27 01:16:38 EDT 2025
Thu Aug 21 18:19:53 EDT 2025
Fri Sep 05 05:53:26 EDT 2025
Fri Sep 05 08:17:02 EDT 2025
Fri Jul 25 10:34:38 EDT 2025
Tue Jun 17 20:55:28 EDT 2025
Tue Jun 10 20:43:36 EDT 2025
Wed Feb 19 01:52:04 EST 2025
Thu Apr 24 23:08:56 EDT 2025
Tue Jul 01 01:32:02 EDT 2025
Sat Sep 06 07:22:19 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Hospital Discharge Database
Pneumococcal Vaccination
Influenza Vaccination
Invasive Pneumococcal Disease
Acute Myocardial Infarction
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c627t-36a7bb0caaffe0bf792bbb366d859454b9f08ef007f6a175c6d2ea0a67e7e3fa3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Article-2
ObjectType-Undefined-1
ObjectType-Feature-3
OpenAccessLink https://link.springer.com/10.1186/1471-2458-10-25
PMID 20085658
PQID 1651243938
PQPubID 44782
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_d9be8ba1500844358066c629ed0f0373
pubmedcentral_primary_oai_pubmedcentral_nih_gov_2822825
proquest_miscellaneous_734281334
proquest_miscellaneous_1660429226
proquest_journals_1651243938
gale_infotracmisc_A219035430
gale_infotracacademiconefile_A219035430
pubmed_primary_20085658
crossref_citationtrail_10_1186_1471_2458_10_25
crossref_primary_10_1186_1471_2458_10_25
springer_journals_10_1186_1471_2458_10_25
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2010-01-19
PublicationDateYYYYMMDD 2010-01-19
PublicationDate_xml – month: 01
  year: 2010
  text: 2010-01-19
  day: 19
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle BMC public health
PublicationTitleAbbrev BMC Public Health
PublicationTitleAlternate BMC Public Health
PublicationYear 2010
Publisher BioMed Central
BioMed Central Ltd
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: BMC
References Binder, Binder, Hörkkö, Dewan, Chang, Kieu, Goodyear, Shaw, Palinski, Witztum, Silverman (CR29) 2003; 9
Musher, Rueda, Kaka, Mapara (CR25) 2007; 45
Bartlett, Mundy (CR3) 1995; 24
Puig-Barberà, Belenguer Varea, Goterris Pinto, Brines Benlliure (CR13) 2002; 30
(CR6) 1997; 46
Vila-Corcoles, Ochoa-Gondar, Ester, Sarrá, Ansa, Saún (CR31) 2006; 6
CR18
Ramirez, Aliberti, Mirsaeidi, Peyrani, Filardo, Amir, Moffett, Gordon, Blasi, Bordon (CR24) 2008; 47
Mangtani, Cutts, Hall (CR14) 2003; 3
Cornu, Yzebe, Leophonte, Gaillat, Boissel, Cucherat (CR12) 2001; 19
Lim, Eerden, Laing, Boersma, Karalus, Town, Lewis, Macfarlane (CR39) 2003; 58
Martin (CR30) 1998; 153
Fedson, Musher, Plotkin, Orenstein (CR7) 2003
Huss, Scott, Stuck, Trotter, Egger (CR19) 2009; 180
Vila-Corcoles, Ochoa-Gondar, Hospital, Ansa, Vilanova, Rodríguez, Llor (CR32) 2006; 43
Hausdorff, Feikin, Klugman (CR2) 2005; 5
Zalacain, Torres, Celis, Blanquer, Aspa, Esteban, Menéndez, Blanquer, Borerías (CR5) 2003; 21
Ochoa-Gondar, Vila-Córcoles, de Diego, Arija, Maxenchs, Grive, Martín, Pinyol (CR34) 2008; 8
Moore, Wiffen, Lipsky (CR11) 2000; 1
Lamontagne, Garant, Carvalho, Lanthier, Smieja, Pilon (CR26) 2008; 179
Melegaro, Edmunds (CR16) 2004; 19
Fedson, Liss (CR17) 2004; 22
Fine, Auble, Yealy, Hanusa, Weissfeld, Singer, Coley, Marrie, Kapoor (CR38) 1997; 336
Madjid (CR27) 2008; 179
Vila-Córcoles, Ochoa-Gondar, Rodríguez-Blanco, Raga-Luria, Gómez-Bertomeu (CR35) 2009; 103
Vila-Corcoles, Salsench, Rodriguez-Blanco, Ochoa-Gondar, de Diego, Valdivieso, Hospital, Gomez-Bertomeu, Raga (CR33) 2009; 27
Vila-Corcoles (CR9) 2007; 24
Hansson (CR21) 2005; 352
Vila-Corcoles (CR28) 2009; 266
Fedson (CR8) 1999; 15
Díaz-Guzmán, Díaz-Guzmán, Egido-Herrero, Fuentes (CR37) 2009; 48
Novella, Alonso, Rodriguez-Salvanés, Susi, Reviriego, Escalante, Suárez, Gabriel (CR36) 2008; 61
Madjid, Miller, Zarubaev, Marinich, Kiselev, Lobzin, Filippov, Casscells (CR22) 2007; 28
Fine, Smith, Carson, Meffe, Sankey, Weissfeld, Detsky, Kapoor (CR10) 1994; 154
Vila-Corcoles (CR20) 2008; 8
Marrie (CR4) 2000; 31
Smeeth, Thomas, Hall, Hubbard, Farrington, Vallance (CR23) 2004; 351
Watson, Wilson, Waugh (CR15) 2002; 20
Hosmer, Lemeshow (CR40) 1999
Ortqvist, Hedlund, Kalin (CR1) 2005; 26
C Cornu (1936_CR12) 2001; 19
J Puig-Barberà (1936_CR13) 2002; 30
MJ Fine (1936_CR10) 1994; 154
A Melegaro (1936_CR16) 2004; 19
TJ Marrie (1936_CR4) 2000; 31
A Vila-Corcoles (1936_CR20) 2008; 8
M Madjid (1936_CR27) 2008; 179
GK Hansson (1936_CR21) 2005; 352
F Lamontagne (1936_CR26) 2008; 179
A Vila-Corcoles (1936_CR28) 2009; 266
L Watson (1936_CR15) 2002; 20
1936_CR18
A Vila-Corcoles (1936_CR31) 2006; 6
J Díaz-Guzmán (1936_CR37) 2009; 48
A Vila-Corcoles (1936_CR33) 2009; 27
J Ramirez (1936_CR24) 2008; 47
DM Musher (1936_CR25) 2007; 45
DS Fedson (1936_CR8) 1999; 15
B Novella (1936_CR36) 2008; 61
DS Fedson (1936_CR7) 2003
CJ Binder (1936_CR29) 2003; 9
M Madjid (1936_CR22) 2007; 28
A Vila-Corcoles (1936_CR9) 2007; 24
Centers for Disease Control and Prevention (1936_CR6) 1997; 46
RA Moore (1936_CR11) 2000; 1
A Huss (1936_CR19) 2009; 180
GM Martin (1936_CR30) 1998; 153
A Ortqvist (1936_CR1) 2005; 26
R Zalacain (1936_CR5) 2003; 21
WS Lim (1936_CR39) 2003; 58
WP Hausdorff (1936_CR2) 2005; 5
DW Hosmer (1936_CR40) 1999
MJ Fine (1936_CR38) 1997; 336
A Vila-Córcoles (1936_CR35) 2009; 103
P Mangtani (1936_CR14) 2003; 3
A Vila-Corcoles (1936_CR32) 2006; 43
L Smeeth (1936_CR23) 2004; 351
O Ochoa-Gondar (1936_CR34) 2008; 8
JG Bartlett (1936_CR3) 1995; 24
DS Fedson (1936_CR17) 2004; 22
19000489 - Rev Esp Cardiol. 2008 Nov;61(11):1140-9
15180106 - Eur J Epidemiol. 2004;19(4):353-63
18804355 - Respir Med. 2009 Feb;103(2):309-16
16941367 - Clin Infect Dis. 2006 Oct 1;43(7):860-8
19171174 - Vaccine. 2009 Mar 4;27(10):1504-10
8995086 - N Engl J Med. 1997 Jan 23;336(4):243-50
7477199 - N Engl J Med. 1995 Dec 14;333(24):1618-24
7993150 - Arch Intern Med. 1994 Dec 12-26;154(23):2666-77
11535330 - Vaccine. 2001 Sep 14;19(32):4780-90
9132580 - MMWR Recomm Rep. 1997 Apr 4;46(RR-8):1-24
17440221 - Eur Heart J. 2007 May;28(10):1205-10
19754854 - J Intern Med. 2009 Nov;266(5):432-44
12728155 - Thorax. 2003 May;58(5):377-82
15680778 - Lancet Infect Dis. 2005 Feb;5(2):83-93
19173202 - Rev Neurol. 2009 Jan 16-31;48(2):61-5
12560191 - Lancet Infect Dis. 2003 Feb;3(2):71-8
16388428 - Semin Respir Crit Care Med. 2005 Dec;26(6):563-74
17896829 - Drugs Aging. 2007;24(10):791-800
12608444 - Eur Respir J. 2003 Feb;21(2):294-302
15161070 - Vaccine. 2004 Feb 25;22(8):927-46
19124790 - CMAJ. 2009 Jan 6;180(1):48-58
18582832 - Lancet Infect Dis. 2008 Jul;8(7):405-6
18838444 - CMAJ. 2008 Oct 7;179(8):749-50
18253977 - Cochrane Database Syst Rev. 2008;(1):CD000422
11049791 - Clin Infect Dis. 2000 Oct;31(4):1066-78
17578773 - Clin Infect Dis. 2007 Jul 15;45(2):158-65
16981982 - BMC Public Health. 2006;6:231
18533841 - Clin Infect Dis. 2008 Jul 15;47(2):182-7
10690792 - Drugs Aging. 1999;15 Suppl 1:21-30
12009269 - Vaccine. 2002 May 22;20(17-18):2166-73
11038265 - BMC Fam Pract. 2000;1:1
18838452 - CMAJ. 2008 Oct 7;179(8):773-7
9777964 - Am J Pathol. 1998 Oct;153(4):1319-20
12740573 - Nat Med. 2003 Jun;9(6):736-43
12372207 - Aten Primaria. 2002 Sep 30;30(5):269-81; discussion 281-3
15602021 - N Engl J Med. 2004 Dec 16;351(25):2611-8
18582392 - BMC Public Health. 2008;8:222
15843671 - N Engl J Med. 2005 Apr 21;352(16):1685-95
References_xml – volume: 180
  start-page: 48
  year: 2009
  end-page: 58
  ident: CR19
  article-title: Efficacy of pneumococcal vaccination in adults: a meta-analysis
  publication-title: CMAJ
  doi: 10.1503/cmaj.080734
– volume: 179
  start-page: 749
  issue: 8
  year: 2008
  end-page: 50
  ident: CR27
  article-title: Acute infections, vaccination and prevention of cardiovascular disease
  publication-title: CMAJ
  doi: 10.1503/cmaj.081302
– volume: 103
  start-page: 309
  year: 2009
  end-page: 16
  ident: CR35
  article-title: Epidemiology of community-acquired pneumonia in older adults: a population-based study
  publication-title: Respir Med
  doi: 10.1016/j.rmed.2008.08.006
– ident: CR18
– volume: 153
  start-page: 1319
  year: 1998
  end-page: 20
  ident: CR30
  article-title: Atherosclerosis is the leading cause of death in the developed societies
  publication-title: Am J Pathol
  doi: 10.1016/S0002-9440(10)65677-5
– volume: 352
  start-page: 1685
  year: 2005
  end-page: 95
  ident: CR21
  article-title: Inflammation, atherosclerosis, and coronary artery disease
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra043430
– volume: 8
  start-page: 222
  year: 2008
  ident: CR34
  article-title: The burden of community-acquired pneumonia in the elderly: the Spanish EVAN-65 study
  publication-title: BMC Public Health
  doi: 10.1186/1471-2458-8-222
– volume: 336
  start-page: 243
  issue: 4
  year: 1997
  end-page: 250
  ident: CR38
  article-title: A prediction rule to identify low-risk patients with community-acquired pneumonia
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199701233360402
– start-page: 529
  year: 2003
  end-page: 88
  ident: CR7
  article-title: Pneumococcal polysaccharide vaccine
  publication-title: Vaccines
– volume: 351
  start-page: 2611
  issue: 25
  year: 2004
  end-page: 8
  ident: CR23
  article-title: Risk of myocardial infarction and stroke after acute infection or vaccination
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa041747
– volume: 61
  start-page: 1140
  issue: 11
  year: 2008
  end-page: 9
  ident: CR36
  article-title: Ten-year incidence of fatal and non-fatal myocardial infarction in the elderly population of Madrid. [In Spanish]
  publication-title: Rev Esp Cardiol
  doi: 10.1157/13127845
– volume: 30
  start-page: 269
  year: 2002
  end-page: 81
  ident: CR13
  article-title: Pneumococcal vaccine effectiveness in the elderly. Systematic review and meta-analysis. [In Spanish]
  publication-title: Aten Primaria
  doi: 10.1016/S0212-6567(02)79027-6
– volume: 21
  start-page: 294
  issue: 2
  year: 2003
  end-page: 302
  ident: CR5
  article-title: Community-acquired pneumonia in the elderly: Spanish multicentre study
  publication-title: Eur Respir
  doi: 10.1183/09031936.03.00064102
– volume: 24
  start-page: 1618
  year: 1995
  end-page: 1624
  ident: CR3
  article-title: Community-acquired pneumonia
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199512143332408
– volume: 19
  start-page: 4780
  year: 2001
  end-page: 90
  ident: CR12
  article-title: Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials
  publication-title: Vaccine
  doi: 10.1016/S0264-410X(01)00217-1
– volume: 22
  start-page: 927
  year: 2004
  end-page: 46
  ident: CR17
  article-title: Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2003.09.027
– volume: 27
  start-page: 1504
  year: 2009
  end-page: 10
  ident: CR33
  article-title: Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2009.01.013
– volume: 19
  start-page: 353
  year: 2004
  end-page: 63
  ident: CR16
  article-title: The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: comparison of meta-analyses
  publication-title: Eur J Epidemiol
  doi: 10.1023/B:EJEP.0000024701.94769.98
– volume: 8
  start-page: 405
  year: 2008
  end-page: 6
  ident: CR20
  article-title: Is the pneumococcal polysaccharide vaccine effective in preventing pneumonia?
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(08)70134-8
– volume: 1
  start-page: 1
  year: 2000
  ident: CR11
  article-title: Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials
  publication-title: BMC Fam Pract
  doi: 10.1186/1471-2296-1-1
– volume: 3
  start-page: 71
  year: 2003
  end-page: 8
  ident: CR14
  article-title: Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(03)00514-0
– volume: 9
  start-page: 736
  year: 2003
  end-page: 43
  ident: CR29
  article-title: Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between streptococcus pneumoniae and oxidized LDL
  publication-title: Nat Med
  doi: 10.1038/nm876
– volume: 43
  start-page: 860
  year: 2006
  end-page: 8
  ident: CR32
  article-title: Protective Effects of the 23- Valent Pneumococcal Polysaccharide Vaccine in the Elderly Population
  publication-title: Clin Infect Dis
  doi: 10.1086/507340
– volume: 46
  start-page: 1
  issue: RR-8
  year: 1997
  end-page: 24
  ident: CR6
  article-title: Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practice (ACIP)
  publication-title: MMWR Morb Mortal Wkly Rep
– volume: 28
  start-page: 1205
  year: 2007
  end-page: 10
  ident: CR22
  article-title: Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy- confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehm035
– volume: 179
  start-page: 773
  issue: 8
  year: 2008
  end-page: 7
  ident: CR26
  article-title: pneumococcal vaccination and risk of myocardial infarction
  publication-title: CMAJ
  doi: 10.1503/cmaj.070221
– volume: 48
  start-page: 61
  issue: 2
  year: 2009
  end-page: 5
  ident: CR37
  article-title: Incidence of strokes in Spain: the Iberictus study. Data from the pilot study [in Spanish]
  publication-title: Rev Neurol
– volume: 47
  start-page: 182
  year: 2008
  end-page: 7
  ident: CR24
  article-title: Acute Myocardial Infarction in Hospitalized Patients with Community-Acquired Pneumonia
  publication-title: Clin Infect Dis
  doi: 10.1086/589246
– start-page: 159
  year: 1999
  end-page: 80
  ident: CR40
  publication-title: Applied Survival Analysis. Regression Modeling of Time to Event Data
– volume: 45
  start-page: 158
  year: 2007
  end-page: 65
  ident: CR25
  article-title: The association between pneumococcal pneumonia and acute cardiac events
  publication-title: Clin Infect Dis
  doi: 10.1086/518849
– volume: 5
  start-page: 83
  year: 2005
  end-page: 93
  ident: CR2
  article-title: Epidemiological differences among pneumococcal serotypes
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(05)70083-9
– volume: 266
  start-page: 432
  year: 2009
  end-page: 44
  ident: CR28
  article-title: Vaccinate your child and save its grandparents from a heart attac? Current perspectives in antipneumococcal vaccination
  publication-title: J Intern Med
  doi: 10.1111/j.1365-2796.2009.02149.x
– volume: 31
  start-page: 1066
  year: 2000
  end-page: 78
  ident: CR4
  article-title: Community-acquired pneumonia in the elderly
  publication-title: Clin Infect Dis
  doi: 10.1086/318124
– volume: 154
  start-page: 2666
  year: 1994
  end-page: 77
  ident: CR10
  article-title: Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials
  publication-title: Arch Intern Med
  doi: 10.1001/archinte.1994.00420230051007
– volume: 58
  start-page: 377
  issue: 5
  year: 2003
  end-page: 382
  ident: CR39
  article-title: Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study
  publication-title: Thorax
  doi: 10.1136/thorax.58.5.377
– volume: 6
  start-page: 231
  year: 2006
  ident: CR31
  article-title: Evolution of vacination rates after the implementation of a free systematic pneumococcal vaccination in Catalonian older adults: 4-years follw-up
  publication-title: BMC Public Health
  doi: 10.1186/1471-2458-6-231
– volume: 20
  start-page: 2166
  year: 2002
  end-page: 73
  ident: CR15
  article-title: Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults
  publication-title: Vaccine
  doi: 10.1016/S0264-410X(02)00112-3
– volume: 26
  start-page: 563
  issue: 6
  year: 2005
  end-page: 74
  ident: CR1
  article-title: Streptococcus pneumoniae: epidemiology, risk factors, and clinical features
  publication-title: Semin Respir Crit Care Med
  doi: 10.1055/s-2005-925523
– volume: 15
  start-page: 21
  issue: Suppl 1
  year: 1999
  end-page: 30
  ident: CR8
  article-title: Pneumococcal vaccination for older adults: the first 20 years
  publication-title: Drugs Aging
  doi: 10.2165/00002512-199915001-00003
– volume: 24
  start-page: 791
  year: 2007
  end-page: 800
  ident: CR9
  article-title: Advances in pneumococcal vaccines: what are the advantages for the elderly?
  publication-title: Drugs Aging
  doi: 10.2165/00002512-200724100-00001
– start-page: 529
  volume-title: Vaccines
  year: 2003
  ident: 1936_CR7
– volume: 48
  start-page: 61
  issue: 2
  year: 2009
  ident: 1936_CR37
  publication-title: Rev Neurol
– volume: 43
  start-page: 860
  year: 2006
  ident: 1936_CR32
  publication-title: Clin Infect Dis
  doi: 10.1086/507340
– volume: 179
  start-page: 749
  issue: 8
  year: 2008
  ident: 1936_CR27
  publication-title: CMAJ
  doi: 10.1503/cmaj.081302
– volume: 1
  start-page: 1
  year: 2000
  ident: 1936_CR11
  publication-title: BMC Fam Pract
  doi: 10.1186/1471-2296-1-1
– volume: 45
  start-page: 158
  year: 2007
  ident: 1936_CR25
  publication-title: Clin Infect Dis
  doi: 10.1086/518849
– ident: 1936_CR18
  doi: 10.1002/14651858.CD000422.pub2
– volume: 9
  start-page: 736
  year: 2003
  ident: 1936_CR29
  publication-title: Nat Med
  doi: 10.1038/nm876
– volume: 19
  start-page: 353
  year: 2004
  ident: 1936_CR16
  publication-title: Eur J Epidemiol
  doi: 10.1023/B:EJEP.0000024701.94769.98
– volume: 352
  start-page: 1685
  year: 2005
  ident: 1936_CR21
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra043430
– volume: 46
  start-page: 1
  issue: RR-8
  year: 1997
  ident: 1936_CR6
  publication-title: MMWR Morb Mortal Wkly Rep
– volume: 24
  start-page: 1618
  year: 1995
  ident: 1936_CR3
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199512143332408
– volume: 26
  start-page: 563
  issue: 6
  year: 2005
  ident: 1936_CR1
  publication-title: Semin Respir Crit Care Med
  doi: 10.1055/s-2005-925523
– volume: 5
  start-page: 83
  year: 2005
  ident: 1936_CR2
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(05)70083-9
– volume: 180
  start-page: 48
  year: 2009
  ident: 1936_CR19
  publication-title: CMAJ
  doi: 10.1503/cmaj.080734
– volume: 8
  start-page: 222
  year: 2008
  ident: 1936_CR34
  publication-title: BMC Public Health
  doi: 10.1186/1471-2458-8-222
– volume: 15
  start-page: 21
  issue: Suppl 1
  year: 1999
  ident: 1936_CR8
  publication-title: Drugs Aging
  doi: 10.2165/00002512-199915001-00003
– volume: 266
  start-page: 432
  year: 2009
  ident: 1936_CR28
  publication-title: J Intern Med
  doi: 10.1111/j.1365-2796.2009.02149.x
– volume: 8
  start-page: 405
  year: 2008
  ident: 1936_CR20
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(08)70134-8
– volume: 351
  start-page: 2611
  issue: 25
  year: 2004
  ident: 1936_CR23
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa041747
– volume: 27
  start-page: 1504
  year: 2009
  ident: 1936_CR33
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2009.01.013
– volume: 6
  start-page: 231
  year: 2006
  ident: 1936_CR31
  publication-title: BMC Public Health
  doi: 10.1186/1471-2458-6-231
– volume: 31
  start-page: 1066
  year: 2000
  ident: 1936_CR4
  publication-title: Clin Infect Dis
  doi: 10.1086/318124
– volume: 58
  start-page: 377
  issue: 5
  year: 2003
  ident: 1936_CR39
  publication-title: Thorax
  doi: 10.1136/thorax.58.5.377
– volume: 19
  start-page: 4780
  year: 2001
  ident: 1936_CR12
  publication-title: Vaccine
  doi: 10.1016/S0264-410X(01)00217-1
– volume: 47
  start-page: 182
  year: 2008
  ident: 1936_CR24
  publication-title: Clin Infect Dis
  doi: 10.1086/589246
– volume: 20
  start-page: 2166
  year: 2002
  ident: 1936_CR15
  publication-title: Vaccine
  doi: 10.1016/S0264-410X(02)00112-3
– volume: 103
  start-page: 309
  year: 2009
  ident: 1936_CR35
  publication-title: Respir Med
  doi: 10.1016/j.rmed.2008.08.006
– volume: 30
  start-page: 269
  year: 2002
  ident: 1936_CR13
  publication-title: Aten Primaria
  doi: 10.1016/S0212-6567(02)79027-6
– volume: 28
  start-page: 1205
  year: 2007
  ident: 1936_CR22
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehm035
– start-page: 159
  volume-title: Applied Survival Analysis. Regression Modeling of Time to Event Data
  year: 1999
  ident: 1936_CR40
– volume: 24
  start-page: 791
  year: 2007
  ident: 1936_CR9
  publication-title: Drugs Aging
  doi: 10.2165/00002512-200724100-00001
– volume: 336
  start-page: 243
  issue: 4
  year: 1997
  ident: 1936_CR38
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199701233360402
– volume: 21
  start-page: 294
  issue: 2
  year: 2003
  ident: 1936_CR5
  publication-title: Eur Respir
  doi: 10.1183/09031936.03.00064102
– volume: 22
  start-page: 927
  year: 2004
  ident: 1936_CR17
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2003.09.027
– volume: 154
  start-page: 2666
  year: 1994
  ident: 1936_CR10
  publication-title: Arch Intern Med
  doi: 10.1001/archinte.1994.00420230051007
– volume: 3
  start-page: 71
  year: 2003
  ident: 1936_CR14
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(03)00514-0
– volume: 153
  start-page: 1319
  year: 1998
  ident: 1936_CR30
  publication-title: Am J Pathol
  doi: 10.1016/S0002-9440(10)65677-5
– volume: 179
  start-page: 773
  issue: 8
  year: 2008
  ident: 1936_CR26
  publication-title: CMAJ
  doi: 10.1503/cmaj.070221
– volume: 61
  start-page: 1140
  issue: 11
  year: 2008
  ident: 1936_CR36
  publication-title: Rev Esp Cardiol
  doi: 10.1157/13127845
– reference: 12009269 - Vaccine. 2002 May 22;20(17-18):2166-73
– reference: 9777964 - Am J Pathol. 1998 Oct;153(4):1319-20
– reference: 17896829 - Drugs Aging. 2007;24(10):791-800
– reference: 12728155 - Thorax. 2003 May;58(5):377-82
– reference: 18804355 - Respir Med. 2009 Feb;103(2):309-16
– reference: 15602021 - N Engl J Med. 2004 Dec 16;351(25):2611-8
– reference: 12560191 - Lancet Infect Dis. 2003 Feb;3(2):71-8
– reference: 12740573 - Nat Med. 2003 Jun;9(6):736-43
– reference: 17578773 - Clin Infect Dis. 2007 Jul 15;45(2):158-65
– reference: 15161070 - Vaccine. 2004 Feb 25;22(8):927-46
– reference: 9132580 - MMWR Recomm Rep. 1997 Apr 4;46(RR-8):1-24
– reference: 19124790 - CMAJ. 2009 Jan 6;180(1):48-58
– reference: 17440221 - Eur Heart J. 2007 May;28(10):1205-10
– reference: 12608444 - Eur Respir J. 2003 Feb;21(2):294-302
– reference: 19754854 - J Intern Med. 2009 Nov;266(5):432-44
– reference: 7477199 - N Engl J Med. 1995 Dec 14;333(24):1618-24
– reference: 16388428 - Semin Respir Crit Care Med. 2005 Dec;26(6):563-74
– reference: 16981982 - BMC Public Health. 2006;6:231
– reference: 18253977 - Cochrane Database Syst Rev. 2008;(1):CD000422
– reference: 7993150 - Arch Intern Med. 1994 Dec 12-26;154(23):2666-77
– reference: 19171174 - Vaccine. 2009 Mar 4;27(10):1504-10
– reference: 15843671 - N Engl J Med. 2005 Apr 21;352(16):1685-95
– reference: 19173202 - Rev Neurol. 2009 Jan 16-31;48(2):61-5
– reference: 11535330 - Vaccine. 2001 Sep 14;19(32):4780-90
– reference: 8995086 - N Engl J Med. 1997 Jan 23;336(4):243-50
– reference: 18582392 - BMC Public Health. 2008;8:222
– reference: 12372207 - Aten Primaria. 2002 Sep 30;30(5):269-81; discussion 281-3
– reference: 19000489 - Rev Esp Cardiol. 2008 Nov;61(11):1140-9
– reference: 18838452 - CMAJ. 2008 Oct 7;179(8):773-7
– reference: 18838444 - CMAJ. 2008 Oct 7;179(8):749-50
– reference: 10690792 - Drugs Aging. 1999;15 Suppl 1:21-30
– reference: 18582832 - Lancet Infect Dis. 2008 Jul;8(7):405-6
– reference: 16941367 - Clin Infect Dis. 2006 Oct 1;43(7):860-8
– reference: 11049791 - Clin Infect Dis. 2000 Oct;31(4):1066-78
– reference: 15680778 - Lancet Infect Dis. 2005 Feb;5(2):83-93
– reference: 18533841 - Clin Infect Dis. 2008 Jul 15;47(2):182-7
– reference: 15180106 - Eur J Epidemiol. 2004;19(4):353-63
– reference: 11038265 - BMC Fam Pract. 2000;1:1
SSID ssj0017852
Score 2.0425608
Snippet Background The 23-valent polysaccharide pneumococcal vaccine (PPV-23) is recommended for elderly and high-risk people, although its effectiveness is...
The 23-valent polysaccharide pneumococcal vaccine (PPV-23) is recommended for elderly and high-risk people, although its effectiveness is controversial. Some...
Background The 23-valent polysaccharide pneumococcal vaccine (PPV-23) is recommended for elderly and high-risk people, although its effectiveness is...
Doc number: 25 Abstract Background: The 23-valent polysaccharide pneumococcal vaccine (PPV-23) is recommended for elderly and high-risk people, although its...
Background: The 23-valent polysaccharide pneumococcal vaccine (PPV-23) is recommended for elderly and high-risk people, although its effectiveness is...
Abstract Background The 23-valent polysaccharide pneumococcal vaccine (PPV-23) is recommended for elderly and high-risk people, although its effectiveness is...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 25
SubjectTerms Aged
Atherosclerosis
Bacterial pneumonia
Biostatistics
Cohort analysis
Cohort Studies
Community-Acquired Infections - prevention & control
Complications and side effects
Data Interpretation, Statistical
Disease prevention
Environmental Health
Epidemiology
Female
Heart attack
Heart attacks
Hospitals
Humans
Immunization
Influenza
Male
Medicine
Medicine & Public Health
Middle Aged
Myocardial infarction
Myocardial Infarction - prevention & control
Outcome Assessment (Health Care)
Pneumococcal vaccine
Pneumococcal Vaccines
Pneumonia
Pneumonia, Pneumococcal - epidemiology
Pneumonia, Pneumococcal - prevention & control
Prevention
Primary care
Public Health
Research Design
Risk factors
Streptococcus infections
Streptococcus pneumoniae
Stroke (Disease)
Stroke - prevention & control
Study Protocol
Vaccine
Vaccines
SummonAdditionalLinks – databaseName: DOAJ: Directory of Open Access Journal (DOAJ)
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEA_SJ0HEb1erRBBUcO3uZjeb-HYWSxUUUQt9WyZfetjulXZP6J_jf-rMJnfcVosvvm4m2WQymfySTH5h7KlvwAFok4dCVHnt0Q9qDTovVXDWhQpUGNk-P8r9g_r9YXO48dQXxYRFeuCouB2njVcGELcUqq7p0E5KKyvtXYHFtyPPJ05jq8VUOj9o1fjWTomuN6_qRiVSn1LJnfU38kD0QvbGfDTS9v_pnDdmp4uRkxeOT8dZae8Gu57gJJ_FZtxkV3x_i12Le3E8XjG6zX59Tjt-nkPvuBuDNvgicAR_fHf2afbh3Rc-8sy-5pHNOLlAkjnp_fJ4gW4TO5P_BGvncf-QwzeYI7bkNl4xGc5zsBRW7F3K08_hJQe7HDw_Pscpk0zxiKNF49iKJWBlzobTxQ9_hx3svf26u5-npxly1H075EJCa0xhAbBWhQmtrowxQkqnGl03tdGhUD4gAAkSEKFY6SoPBcjWt14EEHfZVr_o_X3GTfAgnUbBGpfpQSmDKzgsva2ch1aGjL1adVBnE285PZ9x1I3rFyU76tGOepS-VE3Gnq8znETKjstF31CPr8WIa3v8gBbYJQvs_mWBGXtG9tKRR8CKWUgXG7B5xK3VzXBSKERTiyJj2xNJHMl2mryyuC55krOulAjJEDUKlbEn62TKSdFxvV8sSUYSrkAknTF-iUwrcKFZClFn7F604XWrKQQGcT3-oJ1Y90Qt05R-_n2kIqcgZEV6fLEaBxs1_7vOH_wPnT9kV2MYR5mXepttDadL_wjR4WAej47gN1LwYH8
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Technology Collection
  dbid: 8FG
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgvCAhxDcZAxkJCZAIS-LEcXhBZaIMJBACJu0tOn-Nii3p2hRpfw7_KXeJW9rBeI3Pju07353P558Ze-IKsACVjn0isjh3qAerCqo4Vd4a6zNQvkf7_CT3D_IPh8VhCLjNQ1rlUif2itq2hmLku6lE04TWU6jX09OYXo2i09XwhMZldiXNUJLopvj43eoUoVRFFuB8UiV3U1TEcZYXPZ4pvY29Zol6wP6_1fKaXTqfM3nu4LS3R-Mb7HpwJPlo4PxNdsk1t9i1IQrHh8tFt9mvLyHW5zg0lts-XYO3nqPbx_dGn0cf33_lPcLsKz7gGAflRzTTxi1OWlSYyEb-E4yZDJFDDkcwQa-Sm-FySXcWg6GEYmdDnWYCLziYRef4yRkaSxLCY46yjKtqaAE7M-9m7Q93hx2M337b24_DowyxkVnZxUJCqXViALBXifZllWmthZRWFVVe5LryiXIeXQ8vAX0TI23mIAFZutIJD-Iu22raxt1nXHsH0lZImOMG3Sulce-GrZeZdVBKH7GXSwbVJiCW08MZx3W_c1GyJo7WxFH6khURe7aqMB3AOi4mfUMcX5ERynb_oZ0d1WHR1rbSTmlAnzlReU4HxlLiLFTOJijapYjYU5KXmnQBdsxAuNKAwyNUrXqE5iARRS6SiO1sUOIaNpvFS4mrgw6Z138kPmKPV8VUk_LiGtcuiEaSR4E-dMT4BTSlwC1mKkQesXuDDK9GTckv6NHjD8oN6d6Yls2SZvK9ByGn9GNF8_h8uQ7Wev7vOd_-_ygfsKtDakYap9UO2-pmC_cQPb5OP-qX9W8Jm1cq
  priority: 102
  providerName: ProQuest
– databaseName: SpringerLink Journals (ICM)
  dbid: U2A
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ta9UwFA5zgggiOt-qUyIIKlhtmzZJ_VaHYwoTUS_sWzl5mxe3dtz1Cvs5_lNP0tzLOrcPfm1O0jTnJU-Sk6eEvLAVGIBapS5jRVpajIN1DXWaS2e0cQVIF9g-v_C9Wfn5oDrYIPnqLkzIdl8dSYZIHdxa8nc5htG0KKvARlpU18j1ylsPmvCsaNYHB0JWRWTwuaTSZPIJHP3_RuJzU9HFNMkLZ6VhCtq9Q25H7EibUdl3yYbttsiN_Xg6vkVujXtwdLxadI_8-RZ3-iyFzlATkjVo7yiCPrrTfG32P32ngV_2PR1ZjGPo8zInnV0e9xguUYn0N2h8RWiNwiHMEVNSPV4tGc5S0D6d2JpYp5vDGwp6OVh6fIZTpTfBI4qWjD41toCdOR0W_S97n8x2P_7Y2UvjLxlSzQsxpIyDUCrTANirTDlRF0opxrmRVV1WpapdJq1D4OE4IDLR3BQWMuDCCsscsAdks-s7-4hQ5SxwU6NgictzJ6XClRu2LgpjQXCXkLcrXbU68pX732YctWHdInnrldt65fonRZWQV-sKJyNVx9WiH7zy12KeYzs86BeHbXTZ1tTKSgWImDNZlv64mHMchdqaDA1bsIS89KbT-kiAHdMQLzTg53lOrbbBySBjVcmyhGxPJNGD9bR4ZXxtjCCnbc4RiiFaZDIhz9fFvqbPiutsv_Qy3OMJRNAJoVfICIYLzJyxMiEPR3Nef7VPfUE8jy8QE0OfDMu0pJv_DBTkPvlY-nF8vXKJcz2_fMwf_4fsE3JzzNLI07zeJpvDYmmfIvgb1LPg7n8BljRVsg
  priority: 102
  providerName: Springer Nature
Title Rationale and design of the CAPAMIS study: Effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke
URI https://link.springer.com/article/10.1186/1471-2458-10-25
https://www.ncbi.nlm.nih.gov/pubmed/20085658
https://www.proquest.com/docview/1651243938
https://www.proquest.com/docview/1660429226
https://www.proquest.com/docview/734281334
https://pubmed.ncbi.nlm.nih.gov/PMC2822825
https://doaj.org/article/d9be8ba1500844358066c629ed0f0373
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVADU
  databaseName: BioMed Central_OA刊
  customDbUrl:
  eissn: 1471-2458
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: RBZ
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.biomedcentral.com/search/
  providerName: BioMedCentral
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1471-2458
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: KQ8
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1471-2458
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: DOA
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVEBS
  databaseName: EBSCOhost Academic Search Ultimate
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 1471-2458
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: ABDBF
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1471-2458
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: DIK
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: Geneva Foundation for Medical Education and Research Open Access Journals
  customDbUrl:
  eissn: 1471-2458
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources (ISSN International Center)
  customDbUrl:
  eissn: 1471-2458
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: M~E
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1471-2458
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: RPM
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: Health & Medical Collection (ProQuest)
  customDbUrl:
  eissn: 1471-2458
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: 7X7
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1471-2458
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: BENPR
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Technology Collection
  customDbUrl:
  eissn: 1471-2458
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: 8FG
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/technologycollection1
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Public Health Database (ProQuest)
  customDbUrl:
  eissn: 1471-2458
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: 8C1
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/publichealth
  providerName: ProQuest
– providerCode: PRVFZP
  databaseName: Scholars Portal Open Access Journals
  customDbUrl:
  eissn: 1471-2458
  dateEnd: 20250131
  omitProxy: true
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: M48
  dateStart: 20011001
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
– providerCode: PRVAVX
  databaseName: HAS SpringerNature Open Access 2022
  customDbUrl:
  eissn: 1471-2458
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: AAJSJ
  dateStart: 20011201
  isFulltext: true
  titleUrlDefault: https://www.springernature.com
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: Springer Nature OA Free Journals
  customDbUrl:
  eissn: 1471-2458
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: C6C
  dateStart: 20011201
  isFulltext: true
  titleUrlDefault: http://www.springeropen.com/
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: SpringerLink Journals (ICM)
  customDbUrl:
  eissn: 1471-2458
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: U2A
  dateStart: 20011201
  isFulltext: true
  titleUrlDefault: http://www.springerlink.com/journals/
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1tb9MwELbY9gUJId4JjMpIiBeJjLzaDhJCbbUykDZNhUoVXyI7sUdFl3RdiujP4Z9y56TdMjrxxVLjc-r47nyP7fMdIS90LHMpE-UaLwzcSMM8mCQycX1h8iw3gRTGRvs8Ygej6Ms4Hl-kKm0G8Hzj0g7zSY3m073fZ8uPoPAfrMIL9s6HCdYNotjGKQ3il7MzF7NK4elrk2Jji-yApQpQ6g-ji1MGLmxGnnX7JvTPhne2rJYN7v_vFH7Jhl31r7xyyGpt1-AOud2ATtqtpeQuuaGLe-RWvWNH64tI98mfYbMvqKkscppb1w5aGgoQkfa7x93Dz1-pjUb7ntZeIM1EiTSzQi9OS5hcgeX0l8yySb3LSOWJnAACpVl9EaVaujJD52OdN22KiXxLZbaoND1dgmFFgZ1S4ARoYP0G6Mx5NS9_6gdkNNj_1j9wmwQObsYCXrkhk1wpL5MSeuUpw5NAKRUylos4ieJIJcYT2gBMMUwCjslYHmjpScY116GR4UOyXZSFfkyoMlqyPAHCCBbzRggF6zx4Ow9yLTkzDtlbMSjNmujmmGRjmtpVjmApcjRFjuKTIHbI63WDWR3Y43rSHnJ8TYYRue2Dcn6SNgqe5onSQknA156IIjxcZgxGIdG5B2rAQ4e8QnlJUZKhY5lsrj_A52EErrQLpsML4yj0HLLbogR9z9rVK4lLV-qS-gyAG2DLUDjk-boaW6IPXaHLBdIwRB-Atx1Cr6HhISxH_TCMHPKoluH1V6OjDKB_-APeku7WsLRriskPG7AcXZUFjuOblR5c6vnmMX_y_y4-JTdrVw7f9ZNdsl3NF_oZIMRKdcgWH3MoRd_HcvCpQ3Z6-0fHQ_jVZ_2O3Xnp2MkAymHvO5SjoPsX3nhs1Q
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3ZbtQw0CrlASSEuAkUMBIIkAhNnMRxkBBaCtUuPYSglfYt-Cwr2qTsZkH7OfwA38hMjmW3UN76Go8d23Pb4xlCHtlEGikz5bsgYn5sQQ5mmcz8UDijjWNSuDrb5y7v78fvh8lwhfzq3sJgWGUnE2tBbUqNZ-TrIQfVBNozEq-Pv_lYNQpvV7sSGg1ZbNnZD3DZJq8GbwG_jxnbfLe30ffbqgK-5iyt_IjLVKlAS-mcDZRLM6aUijg3IsniJFaZC4R1oDsdl6BcNTfMykDy1KY2cjKCcc-R83EUxJirPx3OHTwsdM_a9EGh4OshCH6fxUmdPxVrcS9ovrpAwN9qYEEPnozRPHFRW-u_zSvkcmu40l5DaVfJii2ukUvNqR9tHjNdJz8_tmeLlsrCUFOHh9DSUTAz6UbvQ29n8InWGW1f0iZvcitsEea4sNOjEgQ0kA39LrUeNSeVVB7IEVixVDePWaqZLzUGMFvT9ilG8jmVelpZejQD5YxEf0iBdwBdzQgwmUk1Lr_aG2T_TNB1k6wWZWFvE6qcldxkABinMXNCKPAVYfSUGStT7jzyokNQrtsM6Vio4zCvPSXBc8RojhjFLyzxyNN5h-MmOcjpoG8Q43MwzOpdfyjHB3krJHKTKSuUBBs9EHGMF9Scwy5k1gTASmnkkSdILznKHpiYlu0TClgeZvHKe6B-gigB0vTI2hIkyAy93NxRXN7KrEn-h8M88nDejD0xDq-w5RRhOFowYLN7hJ4Ck0bg0oZRFHvkVkPD81VjsA14EPCDdIm6l7ZluaUYfamTnmO4s8B9fNbxwcLM_73nd_6_ygfkQn9vZzvfHuxu3SUXm7CQ0A-zNbJajaf2Hliblbpfszgln89apvwGveyWFA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1tT9UwFG4UEmJijOLbFLUmJmriYFu3tvPbRG_gKoSIJHxbTtcWb4SN3Ltrws_xn3q69d4whA9-XU-7ruelT9vTZ4S8MRlogFyFNmJJmBqMg3kOeRhLqyttE5C2Y_vc5ztH6fg4O_a5ObNFtvviSLK_0-BYmup261zb3sUl34oxpIZJmnXMpEl2m6zKLOe49lotivHheHmMIGSWeD6fa6oNpqKOsf_fuHxpYrqaNHnl5LSbkEb3yT2PJGnRq_4BuWXqdbK258_K18ndfkeO9heNHpI_3_2-n6FQa6q71A3aWIoQkG4XB8Xe7iHt2GY_0p7T2AdCJ3Nem_lZg8ETVUp_Q4Wv6FqjcAITRJi06i-atBchVC652Ghfp57ABwrVvDX07AInTmeQpxTtGj2sbwE7M2unzS_ziByNvvzY3gn9DxrCiieiDRkHoVRUAWCvImVFniilGOca1ZFmqcptJI1FGGI5IE6puE4MRMCFEYZZYI_JSt3U5imhyhrgOkfBFBfrVkqF6zhsXSTagOA2IJsLXZWVZy93P9E4LbtVjOSlU27plOueJFlA3i0rnPfEHTeLfnLKX4o5xu3uQTM9Kb0DlzpXRipA_BzJNHWHx5zjKORGR2jmggXkrTOd0sUF7FgF_noDfp5j2CoLnBoilqUsCsjGQBL9uRoWL4yv9PFkVsYcgRliRyYD8npZ7Gq6HLnaNHMnwx26QDwdEHqDjGC43IwZSwPypDfn5Ve7RBhE9_gCMTD0wbAMS-rJz46Q3KUiSzeO7xcucann14_5s_-QfUXWDj6Pym-7-1-fkzt9-kYcxvkGWWmnc_MCUWGrXnrf_wtXhF4w
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rationale+and+design+of+the+CAPAMIS+study%3A+effectiveness+of+pneumococcal+vaccination+against+community-acquired+pneumonia%2C+acute+myocardial+infarction+and+stroke&rft.jtitle=BMC+public+health&rft.au=Vila-Corcoles%2C+Angel&rft.au=Hospital-Guardiola%2C+Inmaculada&rft.au=Ochoa-Gondar%2C+Olga&rft.au=de+Diego%2C+Cinta&rft.date=2010-01-19&rft.issn=1471-2458&rft.eissn=1471-2458&rft.volume=10&rft.spage=25&rft_id=info:doi/10.1186%2F1471-2458-10-25&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2458&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2458&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2458&client=summon